ES2128404T3 - Derivados de dibekacina y derivados de arbekacina activos contra bacterias resistentes, y la produccion de los mismos. - Google Patents

Derivados de dibekacina y derivados de arbekacina activos contra bacterias resistentes, y la produccion de los mismos.

Info

Publication number
ES2128404T3
ES2128404T3 ES93402870T ES93402870T ES2128404T3 ES 2128404 T3 ES2128404 T3 ES 2128404T3 ES 93402870 T ES93402870 T ES 93402870T ES 93402870 T ES93402870 T ES 93402870T ES 2128404 T3 ES2128404 T3 ES 2128404T3
Authority
ES
Spain
Prior art keywords
derivatives
amino
dibekacina
arbekacina
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93402870T
Other languages
English (en)
Inventor
Shinichi Kondo
Seiji Shibahara
Takayuki Usui
Toshiaki Kudo
Shuichi Gomi
Atsushi Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbial Chemistry Research Foundation
Original Assignee
Microbial Chemistry Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP34131492A external-priority patent/JP3215732B2/ja
Priority claimed from JP24732793A external-priority patent/JP3215759B2/ja
Application filed by Microbial Chemistry Research Foundation filed Critical Microbial Chemistry Research Foundation
Application granted granted Critical
Publication of ES2128404T3 publication Critical patent/ES2128404T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

COMO NUEVOS DERIVADOS DE DIBEKACIN Y NUEVOS DERIVADOS DE ARBECACINA SON AHORA PROVISTOS 2"-AMINO-2"DEOXYDEBECACINA, 2"-AMINO-5,2"DIDEOXIDIBECACIN, 2"-AMINO-2"-DEOXIARBECACINA, 2"-AMINO5,2"DIDEOXIARBECACINA, 2"-AMINO-5,2"-DIDEOXI-5-EPI-FLUORARBECACINA Y 2"-AMINO-5.2"-DIDEOXI-5EPIAMINOARBEKACIN LO CUAL EXHIBE UNA ACTIVIDAD ANTIBACTERIAL ALTA CONTRA UNA AMPLIA VARIEDAD DE BACTERIAS GRAM-POSITIVA Y GRAM-NEGATIVA, INCLUYENDO RESISTENCIA A BACTERIA TAL COMO STAPHYLOCOCCUS AUREUS CON RESISTENCIA A METICILINA Y LOS CUALES TIENEN TOXICIDAD BAJA HACIA LOS MAMIFEROS Y SON UTILES COMO AGENTE ANTIBACTERIAL PARA EL TRATAMIENTO DE LAS INFECCIONES BACTERICIDAS.
ES93402870T 1992-11-27 1993-11-26 Derivados de dibekacina y derivados de arbekacina activos contra bacterias resistentes, y la produccion de los mismos. Expired - Lifetime ES2128404T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34131492A JP3215732B2 (ja) 1992-11-27 1992-11-27 耐性菌に有効なジベカシン誘導体またはアルベカシン誘導体とそれらの製造法
JP24732793A JP3215759B2 (ja) 1993-09-09 1993-09-09 耐性菌に有効な５−置換−２″−アミノ−２″−デオキシアルベカシンとその製造法

Publications (1)

Publication Number Publication Date
ES2128404T3 true ES2128404T3 (es) 1999-05-16

Family

ID=26538214

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93402870T Expired - Lifetime ES2128404T3 (es) 1992-11-27 1993-11-26 Derivados de dibekacina y derivados de arbekacina activos contra bacterias resistentes, y la produccion de los mismos.

Country Status (4)

Country Link
US (2) US5488038A (es)
EP (1) EP0601909B1 (es)
DE (1) DE69322750T2 (es)
ES (1) ES2128404T3 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058880A1 (en) * 2002-07-01 2004-03-25 Chang-Hsing Liang Aminoglycoside antibiotics as novel anti-infective agents
WO2005070945A1 (ja) * 2004-01-21 2005-08-04 Meiji Seika Kaisha, Ltd. メチシリン耐性黄色ブドウ球菌（ｍｒｓａ）に有効な新規アミノグリコシド系抗生物質
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
ES2388420T3 (es) * 2004-05-17 2012-10-15 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
GB0411948D0 (en) * 2004-05-28 2004-06-30 Univ Leeds Compounds
KR101067266B1 (ko) * 2005-08-29 2011-09-23 아지노모토 가부시키가이샤 영양 조성물
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
AU2009299118B2 (en) 2008-10-03 2015-12-17 Glycan Biosciences Llc Anionic conjugates of glycosylated bacterial metabolite
MX2012009028A (es) 2010-02-03 2012-10-15 Microbial Chem Res Found Inductor de lectura traspasada y agente terapeutico para enfermedades geneticas de tipo mutacion sin sentido.
CN116462721B (zh) * 2023-04-18 2024-02-02 江南大学 抗菌性氨基糖苷衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001208A (en) 1972-10-06 1977-01-04 Zaidan Hojin Biseibutsu Kagaku Kenkyo Kai 1-N-[(S)-α-hydroxy-ω-aminoacyl]
US4107424A (en) * 1972-10-06 1978-08-15 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai 1-N-[(S)-α-hydroxy-ω-aminoacyl] derivatives of 3',4'-dideoxykanamycin B and 3'-deoxykanamycin B antibiotics
US3974198A (en) 1975-09-02 1976-08-10 General Electric Company Process for producing methyltriacetoxysilane
JPS6029720B2 (ja) * 1975-12-11 1985-07-12 財団法人微生物化学研究会 ３′，４′‐ジデオキシカナマイシンｂの新規な製造法
US4187372A (en) * 1976-09-08 1980-02-05 Abbott Laboratories Seldomycin factor 5 derivative
IE48972B1 (en) 1978-11-11 1985-06-26 Microbial Chem Res Found The production of a selectively protected n-acylated derivative of an aminoglycosidic antibiotic
JPS631319A (ja) 1986-06-18 1988-01-06 多摩川精機株式会社 Ａｃ機器動作検出回路
JPS6339891A (ja) * 1986-08-04 1988-02-20 Microbial Chem Res Found ５−デオキシ−５−フルオロカナマイシンｂ誘導体とその製造法
JPH0764866B2 (ja) * 1987-02-24 1995-07-12 財団法人微生物化学研究会 １−ｎ−（４−アミノ−３−フルオロ−２−ヒドロキシブチリル）カナマイシン類

Also Published As

Publication number Publication date
EP0601909A3 (en) 1997-03-19
US5488038A (en) 1996-01-30
US5618795A (en) 1997-04-08
EP0601909A2 (en) 1994-06-15
EP0601909B1 (en) 1998-12-23
DE69322750D1 (de) 1999-02-04
DE69322750T2 (de) 1999-08-19

Similar Documents

Publication Publication Date Title
UY25330A1 (es) Nuevos macrólidos
ES2067325T3 (es) Amidas de factores del antibiotico ge 2270.
ES2128404T3 (es) Derivados de dibekacina y derivados de arbekacina activos contra bacterias resistentes, y la produccion de los mismos.
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
BR0210791A (pt) Composição tendo atividade bacteristática e bactericida contra esporos bacterianos e células vegetativas e processo para tratamento de alimentos utilizando a mesma
DE69942977D1 (de) Pharmazeutische zusammenstellungen zur behandlung von hautzuständen
AR017972A1 (es) Composicion antimicrobiana, y uso de la misma para preparar una composicion para controlar staphylococcus aureaus (mrsa) y serratia marcescens atcc 14756
GT199800074A (es) Derivados de la 9-oxima eritromicina.
PA8524501A1 (es) Antibioticos macrolidos
ES2162796T3 (es) Proteinas biocidas.
PY0000170A (es) 2-(hydroxyo-n-(5-nitor-2-thiazolyl) benzamide
ES2133722T3 (es) Utilizacion de dextranos simples o conjugados para la fabricacion de un medicamento para prevenir o reducir el riesgo de infeccion de germenes patogenos bacterianos.
GT198302370A (es) Mejoras en o relativas a antibioticos
ATE272397T1 (de) Selektive antibakterielle zusammensetzungen
ES2178761T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de infe cciones cutaneas.
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
KR950026524A (ko) 피부질환 치료용 의약조성물
MXPA02007371A (es) Utilizacion de compuestos tipo retinoide como agentes antibacterianos.
ES2144154T3 (es) Derivados de eritromicina a 9-0-oxima dotados de actividad antibiotica.
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico
Kobayashi et al. Brief Report Bactericidal Effects of Antiseptics and Disinfectants Against Methicillin-Resistant Staphylococcus aureus
AR039727A1 (es) Difluorotioacetamidas de oxazolidinonas como agentes antibacterianos y composicion farmaceutica en base a ellas
ES468662A1 (es) Procedimiento para producir derivados cefalosporinicos de utilidad terapeutica
ES2108149T3 (es) Derivado de cefalosporina.
AR025379A1 (es) 9a-azalidas con actividad antibacteriana.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 601909

Country of ref document: ES